Other

Valeant: We'll bump Allergan offer to $200 a share

The Canadian drugmaker Valeant said it would be willing to raise its takeover bid for Allergan by almost 12 percent, which would mean $200 or more per share for the maker of Botox.

Other

AstraZeneca profits tumble in third quarter

British pharmaceuticals group AstraZeneca announced on Thursday a slump in quarterly profits, in part on higher investment costs, but raised its outlook for full-year revenues.

Health

UK rejects attempt to challenge assisted suicide laws

Britain's High Court has denied a bid by a terminally ill man to challenge the law on assisted suicide, ruling that the issue was already considered in recent years and does not merit further analysis.

page 5 from 5